Caribou Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in two upcoming investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, will join a panel on cell therapies in autoimmune disorders at Citi's 2024 Global Healthcare Conference in Miami on December 3 at 2:30 PM EST. She will also participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 4 at 10:25 AM EST. Webcasts of both events will be available on Caribou's website for 30 days following the presentations.

BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences:

• Citi's 2024 Global Healthcare Conference, Miami, FL
  December 3, 2024, panel at 2:30 PM EST
  Panel title: Cell therapies in autoimmune disorders
  Webcast

• 7th Annual Evercore ISI HealthCONx Conference, Coral Gables, FL
  December 4, 2024, fireside chat at 10:25 AM EST
  Webcast

For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.

About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com 

Media:
Peggy Vorwald, PhD
media@cariboubio.com 

FAQ

When is Caribou Biosciences (CRBU) presenting at Citi's 2024 Global Healthcare Conference?

Caribou Biosciences will present at Citi's 2024 Global Healthcare Conference on December 3, 2024, at 2:30 PM EST in Miami, FL.

What is the topic of Caribou Biosciences' (CRBU) panel at the Citi Healthcare Conference 2024?

The panel discussion will focus on cell therapies in autoimmune disorders.

When can investors watch the webcasts of Caribou Biosciences' (CRBU) December 2024 conference presentations?

The webcasts will be available on Caribou's website for 30 days after each event.

Which investor conferences is Caribou Biosciences (CRBU) attending in December 2024?

Caribou Biosciences is attending Citi's 2024 Global Healthcare Conference on December 3 and the 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024.